3-Deoxyglucosone Induced Acute Glucose Intolerance in Sprague-Dawley Rats: Involvement of Insulin Resistance and Impaired β-cell Function

Abstract

A recent study found an increased level of 3DG during oral glucose load in healthy individuals, which redirects our attention to the effect of high plasma 3DG level in the pathophysiology of type 2 diabetes mellitus. We found previously that abnormally elevated plasma 3DG was significantly associated with the impaired glucose regulation in non-diabetic seniors. The current study aimed to investigate the acute effects of exogenous 3DG on plasma 3DG levels, glucose tolerance and insulin levels. A significant increase in the plasma level of 3DG was observed in rats administrated 50 mg/kg 3DG i. v. even 2 h after. With the acute elevation of circulating 3DG, intravenous glucose tolerance of normal rats was impaired, whereas plasma insulin levels were higher. The 3DG-mediated impairment in glucose tolerance was associated with the attenuated insulin-stimulated glucose uptake in the adipose and liver tissues and the decreased glucose-stimulated insulin secretion in the pancreas tissue. In rats treated with 50 mg/kg 3DG i. v., a reduced phosphorylation of p85-PI3K was observed in both the liver and pancreas tissues. The increase in plasma levels of 3DG and the deleterious effects of 3DG were attenuated by aminoguanidine pretreatment. Our results indicated a close association of 3DG with diabetes through participating in inducing acute glucose intolerance involvement of PI3K signaling in healthy individuals. By such a mechanism, a 3DG-targeted intervention to attenuation of the acute elevation of circulating 3DG is promising new therapeutic and prevention strategies for diabetes and its complications.

Key words

diabetes - 3-deoxyglucosone - glucose intolerance - aminoguanidine

^* Contributed equally

• References

• 1 Kusunoki H, Miyata S, Ohara T et al. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 2003; 26: 1889-1894
• 2 Eriksson UJ, Wentzel P, Minhas HS et al. Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. Diabetes 1998; 47: 1960-1966
• 3 Beisswenger PJ, Howell S, Stevens R et al. The role of 3-deoxyglucosone and the activity of its degradative pathways in the etiology of diabetic microvasculardisease. In: O’Brien J, Nursten H, Crabbe M, Ames J. (eds.). The maillard reaction in foods and medicine. Cambridge: Royal Society of Chemistry Press; 1998: 298-303
• 4 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
• 5 Maessen DE, Hanssen NM, Scheijen JL et al. Post-glucose load plasma α-dicarbonyl concentrations are increased in individuals with impaired glucose metabolism and type 2 diabetes: the CODAM study. Diabetes Care 2015; 38: 913-920
• 6 Degen J, Beyer H, Heymann B et al. Dietary influence on urinary excretion of 3-deoxyglucosone and its metabolite 3-deoxyfructose. J Agric Food Chem 2014; 19: 2449-2456
• 7 Hamada Y, Nakamura J, Fujisawa H et al. Effects of glycemic control on plasma 3-deoxyglucosone levels in NIDDM patients. Diabetes Care 1997; 20: 1466-1469
• 8 Beisswenger PJ, Howell SK, O'Dell RM et al. Alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001; 24: 726-732
• 9 Lal S, Kappler F, Walker M et al. Quantitation of 3-deoxyglucosone levels in human plasma. Arch Biochem Biophys 1997; 342: 254-260
• 10 Jiang G, Zhang L, Ji Q et al. Accumulation of plasma 3-deoxyglucosone impaired glucose regulation in Chinese seniors: implication for senile diabetes?. Diabetes Metab Syndr 2012; 6: 140-145
• 11 Niwa T. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl 1999; 731: 23-36
• 12 Kato H, van Chuyen N, Shinoda T et al. Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta 1990; 1035: 71-76
• 13 Jiang GL, Zhang LV, Wang F et al. Synthesis and structure analysis of the 3-deoxyglucosone(3-DG). J Soochow Univ 2011; 27: 60-68
• 14 Zhang L, Jiang G, Yao F et al. Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One 2012; 7: e37865
• 15 Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014; 383: 1068-1083
• 16 Yamada H, Miyata S, Igaki N et al. Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction. J Biol Chem 1994; 269: 20275-20280
• 17 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
• 18 Sakiyama H, Takahashi M, Yamamoto T et al. The internalization and metabolism of 3-deoxyglucosone in human umbilical vein endothelial cells. J Biochem 2006; 139: 245-253
• 19 Sassi-Gaha S, Loughlin DT, Kappler F et al. Two dicarbonyl compounds, 3-deoxyglucosone and methylglyoxal, differentially modulate dermal fibroblasts. Matrix Biol 2010; 29: 127-134
• 20 Pan Y, Qiao QY, Pan LH et al. Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Exp Clin Endocrinol Diabetes 2015; 123: 170-177
• 21 Nomura M, Takahashi T, Nagata N et al. Inhibitory mechanisms of flavonoids on insulin-stimulated glucose uptake in MC3T3-G2/PA6 adipose cells. Biol Pharm Bull 2008; 31: 1403-1409
• 22 Li Z, Shangguan Z, Liu Y et al. Puerarin protects pancreatic β-cell survival via PI3K/Akt signaling pathway. J Mol Endocrinol 2014; 53: 71-79
• 23 Nogueira TC, Anhê GF, Carvalho CR et al. Involvement of phosphatidylinositol-3 kinase/AKT/PKCzeta/lambda pathway in the effect of palmitate on glucose-induced insulin secretion. Pancreas 2008; 37: 309-315
• 24 Kikuchi S, Shinpo K, Moriwaka F et al. Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons: Synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases. J Neurosci Res 1999; 57: 280-289
• 25 Dhar A, Desai KL. Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats. Br J Pharmacol 2010; 159: 166-175
• 26 Kato H, van Chuyen N, Shinoda T et al. Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta 1990; 1035: 71-76